# A Study to Learn About Two or More Vaccines That Are Put Together as One Shot Against Infectious Lung Illnesses, Including COVID-19 and Respiratory Syncytial Virus (RSV).

> **NCT05886777** · PHASE2 · COMPLETED · sponsor: **Pfizer** · enrollment: 1142 (actual)

## Conditions studied

- Healthy Participants

## Interventions

- **BIOLOGICAL:** Combination [RSVpreF+BNTb162b2]
- **BIOLOGICAL:** Bivalent BNT162b2 (original/Omi BA.4/BA.5)
- **BIOLOGICAL:** RSVpreF
- **BIOLOGICAL:** QIV
- **BIOLOGICAL:** Normal Saline Placebo

## Key facts

- **NCT ID:** NCT05886777
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-06-05
- **Primary completion:** 2024-01-01
- **Final completion:** 2024-01-01
- **Target enrollment:** 1142 (ACTUAL)
- **Last updated:** 2024-12-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05886777

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05886777, "A Study to Learn About Two or More Vaccines That Are Put Together as One Shot Against Infectious Lung Illnesses, Including COVID-19 and Respiratory Syncytial Virus (RSV).". Retrieved via AI Analytics 2026-06-14 from https://api.ai-analytics.org/clinical/NCT05886777. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*